BioTuesdays

Category - Features

Alcobra’s ADHD program moving to pediatrics

With the recent start of the first of two pivotal trials in adults with attention deficit hyperactivity disorder (ADHD), Alcobra Pharma (NASDAQ:ADHD) is now turning its attention to advancing its pediatric ADHD program...

In conversation with Bing Yao

As an SVP of AstraZeneca’s (NYSE:AZN) MedImmune unit, Bing Yao heads the Respiratory, Inflammation & Autoimmunity (RIA) Innovative Medicines unit at MedImmune, leading a team dedicated to the strategy...

Anavex readies trial of AZ combo drug

Anavex Life Sciences (OTCQB:AVXL) plans to begin a Phase 1b/2a clinical trial in the first quarter of 2014 of a novel combination drug candidate for the treatment of Alzheimer’s disease (AD). “In preclinical studies, we...

Boston Therapeutics planning pivotal trial

Boston Therapeutics (OTCQB:BTHE) hopes to begin a pivotal Phase 3 trial, by the second or third quarter of 2014, of a chewable tablet that is designed to be taken before meals to reduce post-meal elevation of blood...

Aurinia readies Phase 2b trial in lupus nephritis

Aurinia Pharmaceuticals (TSX-V:AUP) is preparing to begin a Phase 2b clinical trial in the first quarter of 2014 with its voclosporin immunosuppressant in combination with CellCept, the standard of care for treating...

DARA’s sales team goes on a Mission

A new sales and marketing venture with a unit of Mission Pharmacal gives DARA BioSciences (NASDAQ:DARA) a formidable leg up in the oncology supportive care sector to address ongoing areas of medical need. A 20-person...

In conversation with Paul Lem

As CEO and co-founder of closely-held Spartan Bioscience, Dr. Paul Lem has a diverse background in clinical medicine, molecular biology research and as a biotech entrepreneur. Prior to co-founding Spartan in 2005, he...

NeoStem completing enrollment in heart trial

NeoStem (NASDAQ:NBS) is on track to complete enrollment later this year in a Phase 2 clinical trial of a bone marrow-derived cell therapy to treat patients for acute myocardial infarction, with a data readout six-to...

Heat Biologics readies proof-of-concept studies

After a successful $27-million IPO in the summer, Heat Biologics (NASDAQ:HTBX) plans to begin two proof-of-concept trials later this year of its platform to transform living cancer cells into pumps that continually...

CytRx awaiting soft tissue sarcoma data in December

What if it were possible to deliver a broad range of potent cancer drugs more optimally, enhancing both their safety and efficacy? That’s the question CytRx (NASDAQ:CYTR) hopes to answer this December when it plans to...

Subscribe

Sign up to our weekly BioTuesdays newsletter.